Immunotherapy for alzheimer's disease: Past, present and future

Frontiers in Aging Neuroscience

Volumn 6, Issue JUN, 2014, Pages

  Spencer, Brian ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; A ; Blood brain barrier; Immunization; Immunotherapy

Indexed keywords

BAPINEUZUMAB; CRENEZUMAB; GANTENERUMAB; PONEZUMAB; SOLANEZUMAB;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ASSOCIATION CORTEX; BLOOD BRAIN BARRIER; HEALTH CARE QUALITY; IMMUNOTHERAPY; LIMBIC SYSTEM; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW;

EID: 84904556283     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00114     Document Type: Review

References (69)

1. Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., et al. (2012). An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J. Neurosci. 32, 9677-9689. doi: 10.1523/jneurosci.4742-11.2012
2. Allinson, T. M., Parkin, E. T., Turner, A. J., and Hooper, N. M. (2003). ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 74, 342-352. doi: 10.1002/jnr.10737
3. Alzheimer's association. (2013). Alzheimer's Disease Facts and Figures. Alzheimer's and Dementia 9.
4. Anderson, J. P., Chen, Y., Kim, K. S., and Robakis, N. K. (1992). An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence. J. Neurochem. 59, 2328-2331. doi: 10.1111/j.1471-4159.1992.tb10128.x
5. Banks, W. A., Terrell, B., Farr, S. A., Robinson, S. M., Nonaka, N., and Morley, J. E. (2002). Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23, 2223-2226. doi: 10.1016/s0196-9781(02)00261-9
6. Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., et al. (2003). Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U S A 100, 2023-2028. doi: 10.1073/pnas.0436286100
7. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804. doi: 10.1056/NEJMoa1202753
8. Bien-Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., et al. (2014). Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 211, 233-244. doi: 10.1084/jem.20131660
9. Blennow, K., De Leon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403. doi: 10.1016/S0140-6736(06)69113-7
10. Blennow, K., Zetterberg, H., Rinne, J. O., Salloway, S., Wei, J., Black, R., et al. (2012). Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 69, 1002-1010. doi: 10.1001/archneurol.2012.90
11. Boado, R. J., Lu, J. Z., Hui, E. K., Sumbria, R. K., and Pardridge, W. M. (2013). Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol. Bioeng. 110, 1456-1465. doi: 10.1002/bit.24795
12. Boado, R. J., Zhang, Y., Zhang, Y., and Pardridge, W. M. (2007). Genetic engineering, expression and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 97, 1376-1386. doi: 10.1002/bit.21369
13. Boche, D., Donald, J., Love, S., Harris, S., Neal, J. W., Holmes, C., et al. (2010). Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol. 120, 13-20. doi: 10.1007/s00401-010-0705-y
14. Böckenhoff, A., Cramer, S., Wolte, P., Knieling, S., Wohlenberg, C., Gieselmann, V., et al. (2014). Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase a. J. Neurosci. 34, 3122-3129. doi: 10.1523/jneurosci.4785-13.2014
15. Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., et al. (2012). Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28, 49-69. doi: 10.3233/JAD-2011-110977
16. Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259. doi: 10.1007/bf00308809
17. Braak, H., and Braak, E. (1996). Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165, 3-12. doi: 10.1111/j.1600-0404.1996.tb05866.x
18. Burstein, A. H., Zhao, Q., Ross, J., Styren, S., Landen, J. W., Ma, W. W., et al. (2013). Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin. Neuropharmacol. 36, 8-13. doi: 10.1097/wnf.0b013e318279bcfa
19. Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., et al. (2005). Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 25, 9096-9101. doi: 10.1523/jneurosci.1697-05.2005
20. Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H. H., Siemers, E. R., et al. (2013). Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement. 9, 123-131.e1. doi: 10.1016/j.jalz.2012.12.004
21. Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., et al. (2013). Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 5, 183ra57, 1-12. doi: 10.1126/scitranslmed.3005338
22. Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G., and Golde, T. E. (2001). Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22, 721-727. doi: 10.1016/s0197-4580(01)00245-7
23. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., Demattos, R. B., Mathis, C., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457. doi: 10.1038/nn842
24. Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321. doi: 10.1056/NEJMoa1312889
25. Freeman, G. B., Brown, T. P., Wallace, K., and Bales, K. R. (2012a). Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. Curr. Alzheimer Res. 9, 1059-1068. doi: 10.2174/156720512803569064
26. Freeman, G. B., Lin, J. C., Pons, J., and Raha, N. M. (2012b). 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J. Alzheimers Dis. 28, 531-541. doi: 10.3233/JAD-2011-110869
27. Frenkel, D., Kariv, N., and Solomon, B. (2001). Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 19, 2615-2619. doi: 10.1016/s0264-410x(00)00501-6
28. Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., and Starzyk, R. M. (1991). Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. U S A 88, 4771-4775. doi: 10.1073/pnas.88.11.4771
29. Fukuchi, K., Accavitti-Loper, M. A., Kim, H. D., Tahara, K., Cao, Y., Lewis, T. L., et al. (2006). Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem. Biophys. Res. Commun. 344, 79-86. doi: 10.1016/j.bbrc.2006.03.145
30. Garber, K. (2012). Genentech's Alzheimer's antibody trial to study disease prevention. Nat. Biotechnol. 30, 731-732. doi: 10.1038/nbt0812-731
31. Gralle, M., and Ferreira, S. T. (2007). Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog. Neurobiol. 82, 11-32. doi: 10.1016/j.pneurobio.2007.02.001
32. Harris, J. A., Devidze, N., Verret, L., Ho, K., Halabisky, B., Thwin, M. T., et al. (2010). Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68, 428-441. doi: 10.1016/j.neuron.2010.10.020
33. Hussain, M. M., Strickland, D. K., and Bakillah, A. (1999). The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 19, 141-172. doi: 10.1146/annurev.nutr.19.1.141
34. Kasturirangan, S., Brune, D., and Sierks, M. (2009). Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. Biotechnol. Prog. 25, 1054-1063. doi: 10.1002/btpr.190
35. Kasturirangan, S., and Sierks, M. (2010). Targeted hydrolysis of Beta-amyloid with engineered antibody fragment. Curr. Alzheimer Res. 7, 214-222. doi: 10.2174/156720510791050876
36. Kojro, E., and Fahrenholz, F. (2005). The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell. Biochem. 38, 105-127. doi: 10.1007/0-387-23226-5_5
37. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., et al. (2002). Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335.
38. La Porte, S. L., Bollini, S. S., Lanz, T. A., Abdiche, Y. N., Rusnak, A. S., Ho, W. H., et al. (2012). Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Biol. 421, 525-536. doi: 10.1016/j.jmb.2011.11.047
39. Landen, J. W., Zhao, Q., Cohen, S., Borrie, M., Woodward, M., Billing, C. B. Jr., et al. (2013). Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin. Neuropharmacol. 36, 14-23. doi: 10.1097/WNF.0b013e31827db49b
40. Lemere, C. A., and Masliah, E. (2010). Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol. 6, 108-119. doi: 10.1038/nrneurol.2009.219
41. Liu, R., Mcallister, C., Lyubchenko, Y., and Sierks, M. R. (2004). Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry 43, 9999-10007. doi: 10.1021/bi0492354
42. Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., et al. (2005). Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131. doi: 10.1212/01.wnl.0000148590.39911.df
43. Nath, S., Agholme, L., Kurudenkandy, F. R., Granseth, B., Marcusson, J., and Hallbeck, M. (2012). Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid. J. Neurosci. 32, 8767-8777. doi: 10.1523/JNEUROSCI.0615-12.2012
44. Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., et al. (2014). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49-60. doi: 10.1016/j.neuron.2013.10.061
45. NIH. (2014a). Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease (ACCTION) [Online]. Available: http://clinicaltrials.gov/ct2/show/NCT01284387 [Accessed].
46. NIH. (2014b). Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU) [Online]. Available: http://www.clinicaltrials.gov/ct2/show/NCT01760005 [Accessed].
47. NIH. (2014c). Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3) [Online]. Available: http://clinicaltrials.gov/ct2/show/NCT01900665?term=Solanezumab&rank=1 [Accessed].
48. NIH. (2014d). Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy [Online]. Available: http://clinicaltrials.gov/ct2/show/NCT01821118 [Accessed].
49. Okun, E., Mattson, M. P., and Arumugam, T. V. (2010). Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 12, 164-178. doi: 10.1007/s12017-009-8099-5
50. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D. J., et al. (2012). Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198-207. doi: 10.1001/archneurol.2011.1538
51. Patel, A. N., and Jhamandas, J. H. (2012). Neuronal receptors as targets for the action of amyloid-beta protein (Abeta) in the brain. Expert Rev. Mol. Med. 14:e2. doi: 10.1017/s1462399411002134
52. Reiman, E. M., Langbaum, J. B., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., et al. (2011). Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26(Suppl. 3), 321-329. doi: 10.3233/JAD-2011-0059
53. Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., et al. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333. doi: 10.1056/NEJMoa1304839
54. Samadi, H., and Sultzer, D. (2011). Solanezumab for Alzheimer's disease. Expert Opin. Biol. Ther. 11, 787-798. doi: 10.1517/14712598.2011.578573
55. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. doi: 10.1038/22124
56. Schneeberger, A., Mandler, M., Otawa, O., Zauner, W., Mattner, F., and Schmidt, W. (2009). Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J. Nutr. Health Aging 13, 264-267. doi: 10.1007/s12603-009-0070-5
57. Serrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M. B., Maurage, C. A., et al. (2010). Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133, 1312-1327. doi: 10.1093/brain/awq056
58. Shin, S. U., Friden, P., Moran, M., Olson, T., Kang, Y. S., Pardridge, W. M., et al. (1995). Transferrin-antibody fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. U S A 92, 2820-2824. doi: 10.1073/pnas.92.7.2820
59. Sisodia, S. S., and St George-Hyslop, P. H. (2002). γ-Secretase, notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281-290. doi: 10.1038/nrn785
60. Spencer, B. J., and Verma, I. M. (2007). Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. U S A 104, 7594-7599. doi: 10.1073/pnas.0702170104
61. Tayeb, H. O., Murray, E. D., Price, B. H., and Tarazi, F. I. (2013). Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin. Biol. Ther. 13, 1075-1084. doi: 10.1517/14712598.2013.789856
62. Tayeb, H. O., Yang, H. D., Price, B. H., and Tarazi, F. I. (2012). Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol. Ther. 134, 8-25. doi: 10.1016/j.pharmthera.2011.12.002
63. Terry, R., Hansen, L., and Masliah, E. (1994). "Structural basis of the cognitive alterations in Alzheimer disease," in Alzheimer Disease, eds R. Terry and R. Katzman (New York: Raven Press), 179-196.
64. Vassar, R., Kuhn, P. H., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., et al. (2014). Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. doi: 10.1111/jnc.12715. [Epub ahead of print].
65. Waldmann, T. A. (2003). Immunotherapy: past, present and future. Nat. Med. 9, 269-277. doi: 10.1038/nm0303-269
66. Wiessner, C., Wiederhold, K. H., Tissot, A. C., Frey, P., Danner, S., Jacobson, L. H., et al. (2011). The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 31, 9323-9331. doi: 10.1523/jneurosci.0293-11.2011
67. Wilcock, D. M., Gordon, M. N., Ugen, K. E., Gottschall, P. E., Dicarlo, G., Dickey, C., et al. (2001). Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation and congophilic plaque levels. DNA Cell Biol. 20, 731-736. doi: 10.1089/10445490152717596
68. Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., et al. (2012). Safety, tolerability and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 11, 597-604. doi: 10.1016/s1474-4422(12)70140-0
69. Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., et al. (2011). Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3:84. doi: 10.3410/f.10855956.11773054